Prognostic value of circulating tumor cells detected with the CellSearch system in esophageal cancer patients: a systematic review and meta-analysis

Table 1 Characteristics of included studies for the meta-analyses

Reference	Year	Country	Patient		Age (years)	Tumor stage	Sampling time	Target antigen/gene	Cutoff	Positive		End point	Treatment regimens
Reference	Year	Country	number	male/female	Age (years)	Tumor stage	Sampling time	Target antigen/gene	Cutoff	n	male/female	End point	Treatment regimens
Konczalla L 11	2019	Germany	76	27/19	65(NR)	I—IV	Baseline	CK, CD45	≥1/7.5 ml	15	10/5	OS/RFS	Surgery
Woestemeier A 12	2018	Germany	45	35/10	63.3	I—III	Baseline	EpCAM, CK (8, 18, 19), CD45	≥1/7.5 ml	7	6/1	OS/RFS	Surgery
Tanaka M 23	2015	Japan	38	30/8	63 (43–87)	I—IV	Baseline	EpCAM, CK (8, 18, 19), CD45	≥2/7.5 ml	19	14/5	OS	Chemotherapy/Chemoradiotherapy
			38	30/8	63 (43–87)	I—IV	intra-therapy	EpCAM, CK (8, 18, 19), CD45	≥2/7.5 ml	15	NR	OS
Matsushita D 24	2015	Japan	90	78/12	65 (46–98)	II—IV	Baseline	EpCAM, CD45	≥1/7.5 ml	25	22/3	OS	Chemotherapy/Chemoradiotherapy
			71	NR	NR	NR	intra-therapy	EpCAM, CD45	≥1/7.5 ml	15	NR	NR
Reeh M 25	2015	Germany	100	77/23	66 (32–85)	I—IV	Baseline	EpCAM, CK, CD45	≥1/7.5 ml	18	13/5	OS/RFS	Surgery
Sclafani F 26	2014	U.K.	18	16/2	61 (38–78)	NR	Baseline	EpCAM, CK CD45	≥2/7.5 ml	8	NR	OS	NR
Hiraiwa K 27	2008	Japan	38	NR	NR	NR	Baseline	EpCAM, CK CD45	≥2/7.5 ml	5	NR	OS	Chemotherapy

ISSN: 1471-2407